Traded Mar 13 · filed 5 days later
Derivative exercise or conversion — not an open-market buy.
Traded Feb 17, 2026 · Filed Feb 18, 2026
The CEO of ADMA Biologics sold $96K of ADMA Biologics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$96,480
Shares × reported transaction price
36 days after results of Jan 12, 2026, 8 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.9% | +1.0% | −2.9% |
| 30 days | −10.4% | −5.5% | −4.9% |
| 90 days | −46.0% | +6.9% | −52.9% |
| 180 days | −41.6% | +12.6% | −54.2% |
Past results only. Not a forecast.
Traded Mar 13 · filed 5 days later
Derivative exercise or conversion — not an open-market buy.
Traded Mar 17 · filed 1 day later
Gift or transfer — classified separately from trades.
Traded Mar 17 · filed 1 day later
Gift or transfer — classified separately from trades.